Company intelligence / Profile preview
Baxios
- Ownership
- Private
- Development stage
- Other
01
Overview
Baxios is a biotechnology company focused on developing novel therapeutics that target the Bax protein to induce apoptosis in cancer cells. The company's primary focus is on oncology, specifically targeting solid tumors through the modulation of cell death pathways. Baxios utilizes a proprietary platform to identify and develop small molecules and peptides that can effectively activate or inhibit Bax, depending on the therapeutic need. Currently in the pre-clinical stage, the company is working to advance its lead candidates toward clinical trials. Baxios aims to provide more effective and targeted treatment options for patients with various forms of cancer.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeBiologicPeptide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Baxios.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baxios.